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Tumor necrosis factor-alpha (TNF), a mononuclear phagocyte (MO)-derived peptide, 
is increasingly being recognized for its pleomorphic immunologic effects. A number of 
investigations have demonstrated that lipopolysaccharide (LPS) can induce TNF synthesis, 
yet mechanisms that regulate TNF expression at the cellular and molecular levels have not 
been fully elucidated. In this study, we present data demonstrating pentoxifylline, a 
methylxanthine, is efficacious in suppressing LPS-induced MO-derived TNF at the level of 
both TNF mRNA accumulation and TNF supernatant bioactivity. Pentoxifylline, at a dose of 
1 x 10-5M, suppressed the production of both biologically active TNF and TNF mRNA 
expression by more than 50%. Furthermore, additional methylxanthines and dibutyryl 
cAMP have similar effects on TNF expression. These data support the mechanism for this 
suppressive effect is via the generation of intracellular cAMP. © 1988 Aoaoe~io P . . . . .  ~no. 
Tumor necrosis factor-alpha (TNF) is a mononuclear phagocytic cell (MO)-derived 
protein that is being recognized as an important mediator in a variety of physiological and 
immunological processes (1,2). Systemic effects of TNF were first described for its 
oncolytic activity on solid murine tumors (3), but subsequent investigations have 
demonstrated an expanded role for TNF in various diseases. For example, it is now apparent 
that TNF is one of the more proximal mediators responsible for the pathogenesis of 
endotoxin-induced shock (4,5,6). At the cellular level, TNF has significant pleomorphic 
effects on cells which have been shown to orchestrate inflammatory processes; including 
endothelial cells, fibroblasts, polymorphonuclear leukocytes, blood monocytes and 
macrophages, adipocytes, lymphocytes, and osteoclasts (2,7,8). The effects of TNF on 
different cellular populations place this monokine in a pivotal role in modulating acute and 
chronic inflammatory states. 
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Mechanisms that regulate TNF expression at the cellular and molecular levels have 
not been fully clarified. Investigations have demonstrated LPS challenged murine M0 
populations can concomitantly produce both monokine polypeptides (interleuldn-1 and 
TNF), as well as prostaglandin E2 (PGE2), a metabolite of the cyclooxygenase pathway of 
arachidonate acid (9). The concomitant synthesis of PGE2 is an important component in this 
system and may serve as an autocoid for transcriptional and post-transcriptional regulation of 
TNF (10) via the second messenger cAMP. Data regarding TNF expression by other 
pharmacologic agents which may mediate their effects through cAMP is lacking. In the 
present study we demonstrate that pentoxifylline is efficacious in suppressing TNF at the 
level of both TNF mRNA accumulation and TNF supernatant bioactivity. Furthermore, we 
demonstrate that certain methylxanthines, as well as dibutyryl cAMP, have similar 
suppressive effect on TNF expression. Evidence provided via Northern blot analysis and 
bioassay, shows that pentoxifylline and other methylxanthines can induce significant 
regulation of LPS-induced TNF production. 
Materials and Methods 
Macrophage Populations: Immunologically-activated murine (CBA/J) macrophages (M0) 
were recruited by injecting 0.5 ml of complete Freund's adjuvant (CFA) (diluted 1:1 with 
sterile saline) into the peritoneal cavity. After 14 days M0 populations were harvested and 
plated on either 35 mm or 100 mm culture plates (Costar, Cambridge, MA) at a 
concentration of 1 x 106 cells/ml. The cells were allowed to adhere for 2 hrs at 37oc in 5% 
CO2/95% humidified air, and washed twice with complete media prior to further stimulation. 
Various concentrations of test compound were added concomitantly with the LPS challenge. 
At specific time points, supernatants were harvested and total RNA extracted as described 
below. 
Reagents: Pentoxifylline was the generous gift of Hoechst-Roussel Pharmaceuticals, Inc. 
Stock pentoxifylline was prepared at 5 x 10-h-2~M in complete media. Serial dilutions of 
pentoxifylline were prepared in complete media. PGE2 was the generous gift of Upjohn Co. 
PGE2 stock was prepared at 10-2M in ethanol. Serial dilutions of PGE2 were prepared in 
complete media. Stock LPS ~ .  coli 0111:B4, Sigma Chemical Co., St. Louis, MO) was 
prepared at a concentration of 200 ug/ml in complete media. Theophylline, theobromine, 
isobutyl methyl xanthine and dibutyryl cAMP (Sigma Chemical Co) were prepared at 10-2M 
stock solution. 
Tumor Necrosis Assay: 
The TNF bioactivity was quantitated in cell-free supernatants and standardized to the 
number of adherent cells. Bioactivity of TNF was monitored using a semi-automated LM 
fibroblast lyric assay (11). LM cells (5 x 104/100 ~tl) were cultured in 96 well fiat bottom 
microtiter plates for 18 hrs at 37oc, 5% CO2/95% humidified air in the presence of 5 ug/ml 
actinomycin D with serial 1:2 dilutions of test samples. After incubation, plates were washed 
in phosphate buffered saline and the remaining cells were stained with crystal violet (0.5% in 
methanol/water [1:4 v/v]). The quantity of cell lysis was determined using a microELISA 
autoreader. Units of TNF activity were defined using an internal standard of human 
recombinant TNF with a specific activity of 107 units/mg protein (Cetus Corporation, 
Emeryville,CA). To establish specificity of cell lysis for TNF, several test samples were 
incubated concomitantly with specific, rabbit anti-murine TNF neutralizing antibody prior to 
the addition of samples to the targets. 
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Northern Blot Analysis: 
Total RNA from murine M0 were isolated at various time points using a modification 
of the method of Chirgwin et al (12) and Jonas et al (13). Briefly, M0 monolayers were 
scraped into a solution of 25 mM Tris, pH 8.0 containing 4.2M guanidine isothiocyanate, 
0.5% Sarkosyl and 0.1 M 2-mercaptoethanol. After homogenization, an equal volume of 100 
mM Tris, pH 8.0 containing 10 mM EDTA and 1.0% SDS was added and the RNA was 
extracted with chloroform-phenol and chloroform-isoamyl alcohol. The RNA was alcohol 
precipitated, separated by formaldehyde/1% agarose gels, and transblotted to nitrocellulose. 
The baked Northern blots were prehybridized and the hybridized with 32P-5'end labeled 
oligonucleotide probes for TNF (14) and beta-actin (15), respectively (gifts of Dr. Glen 
Andrews and Henry Showell, Pfizer Pharmaceutical Co, Groton, CT). The nucleotide 
sequence for TNF was the 25-mer 5'-GGT-CAC-CCT-TCT-CCA-GCT-GGA-AGA-C-3' 
and the I]eta-actin probe was 42-mer 5'-GGC-TGG-GGT-GTI'-GAA-GGT-CTC-AAA- 
CAT-GAT-CTG-GGT-CAT-CTF-3'. Stringency washed blots were placed at -70oC with 
intensifying screens and the developed autoradiographs quantitated using laser densitometry 
(Ultrascan XL, LXB Instruments, Inc., Houston, TX). Equivalent amounts of total 




Pentoxifylline Suppression of LPS-induced M0-Derived TNF Bioactivity: Cell-free 
supematants from LPS (10 ug/ml) treated MO in the presence or absence of pentoxifylline 
were collected and analyzed for TNF bioactivity. As shown in Figure 1, pentoxifylline 
suppressed LPS-induced TNF production in a dose-dependent manner. Specificity for TNF 
was demonstrated by neutralization of TNF-induced cytotoxicity of LM cells with anti- 
murine TNF antibody. Pentoxifylline in concentrations equivalent to those found in serial 
dilutions did not interfere with the cytotoxicity of preformed TNF in the bioassay. Other 
methylxanthines, such as theobromine, isobutyl methylxanthine, and theophylline, were also 
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Figure 1 Pentoxif-yUine suppression of LPS-induced MO-defived TNF bioactivity in a 
dose-dependent manner. Pentoxifylline significantly reduced TNF production 
by greater than 50% at 1 x 10-5M. 
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Table 1. Effects of various compounds associated with an increase in intracellular cAMP on 
LPS-induced TNF-alpha production. M0s were incubated with the above test compounds 
concomitant with LPS. Cell-free supematants were then collected and assayed for TNF 
activity. The data presented represents the concentration of compound that would induce an 
approximate 50% reduction in the LPS response. 
Sample % Suppression 
LPS (lug/m1) 
LPS + pentoxifylline (2.5 x 10-5M) 
LPS + isobutyl methylxanthines (5 x 10-5M) 
LPS + theophylline (1 x 10-4 M) 
LPS + theobromine (1 x 10-4 M) 
LPS + prostaglandin E2 (1 x 10-7 M) 







above methyl xanthines to block LPS-dependent TNF production is compared to 
pentoxifylline, PGE2, and dibutyryl cAMP. 
Pentoxif-ylline Suppression of LPS-Induced M0-derived TNF mRNA Accumulation: To 
establish the effects of pentoxifylline on TNF mRNA expression, Northern blot analyses 
were performed. Adherent M0 were incubated in presence of LPS (10 ug/ml) alone or LPS 
in the presence of graded doses of pentoxifylline. Total RNA was extracted after 3 hr 
incubation. As shown in Figure 2, Northern blot analysis demonstrated a reduction in TNF 
mRNA in response to various concentrations of pentoxifyUine. The level of TNF mRNA, as 
assessed by laser densitometry, was reduced by 60% and 45% in response to 5 x 10-5M and 
5 x 10-6M, pentoxifylline, respectively. Since methylxanthines and PGE2 can promote the 
accumulation of intraceUular cAMP, it was of interest to establish the role of dibutyryl 
cAMP on LPS-induced TNF mRNA expression. Thus, Northern blot analyses of TNF 
mRNA from M0-treated with LPS alone or in the presence of dibutyryl cAMP were 
performed. As shown in Figure 3, dibutyryl-cAMP significantly suppressed the ability of 
LPS to induce TNF mRNA expression. The accumulation of TNF mRNA in response to 
either 1 ng/ml or 100 ng/ml LPS were susceptible to dibutyryl-cAMP modulation. 
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Northern blot analysis of pentoxffylline suppression of LPS-induced TNF 
mRNA, as assessed by laser densitometry. Expression of TNF mRNA was 
reduced by 60% and 45% in response to 5 x 10-5M and 5 x 10-6M 
pentoxifylline, respectively. MOs were treated with LPS 3 hrs prior to rnRNA 
isolation. 
Discussion 
TNF has become increasingly recognized as an important mediator of diverse 
physiological and immunological processes. TNF in v&o exhibits characteristics which 
support this cytokine as a proximal mediator for the pathogenesis of septic shock (4,5,6). At 
the cellular level, TNF is an important cytokine orchestrating a variety of local immune 
responses, resulting in pleomorphic effects on cellular constituents of inflammation. In this 
study, we demonstrate that pentoxifylline, a methylxanthine, dose-dependently suppressed of 
LPS-induced TNF production at the level of mRNA expression. Other methylxanthines, 
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Northern blot analysis of dibutyryl cAMP suppression of LPS-induced TNF 
mRNA. Dibutyryl cAMP, 10-aMM, resulted in significant suppression of both 
1 and 100 ng/ml LPS. MOs were treated with LPS 3 hrs prior to mRNA 
isolation. 
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such as theobromine, isobutyl methylxanthine, and theoph~lline, as well as PGE2 and 
dibutyryl cAMP, were found to be efficacious in the suppressipn of TNF. Pentoxifylline was 
initially demonstrated to clinically abrogate of claudication in patients with peripheral 
vascular occlusive disease (16). This pharmacologic phenomenon is attributed to enhanced 
vascular wall production of prostacyclin (PGI2) (17) and intracellular cAMP in platelets, 
polymorphonuclear leukocytes and monocytes (17,18). Since cAMP can function in 
intracellular signal translocation and regulate monokine production (19), this mechanism 
may be involved in pentoxifylline-induced inhibition of TNF production. 
The pharmacologic effects of pentoxifylline may have important implications in 
clinical disease states where the local and systemic modulation of TNF may be essential for 
the control of specific inflammatory processes. Investigations regarding the initiation of 
septic shock have provided data which establishes TNF as the proximal mediator in the 
pathogenesis of this disorder (4,5,6). It is interesting to speculate on the potential 
pharmacologic intervention with pentoxifylline, as a means to treat septic shock. 
In conclusion, pentoxifylline can dose dependently suppress TNF production at both 
the mRNA and bioactivity levels. Other methylxanthines, including theobromine, isobutyl 
methylxanthine, and theophylline, as well as PGE2 and dibutyryl cAMP were demonstrated 
to have similar effects in the suppression of TNF. These findings are important with regard 
to understanding mechanisms that regulate the production of MO-derived TNF. 
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